SG11202005606VA - Incretin analogs and uses thereof - Google Patents

Incretin analogs and uses thereof

Info

Publication number
SG11202005606VA
SG11202005606VA SG11202005606VA SG11202005606VA SG11202005606VA SG 11202005606V A SG11202005606V A SG 11202005606VA SG 11202005606V A SG11202005606V A SG 11202005606VA SG 11202005606V A SG11202005606V A SG 11202005606VA SG 11202005606V A SG11202005606V A SG 11202005606VA
Authority
SG
Singapore
Prior art keywords
incretin analogs
incretin
analogs
Prior art date
Application number
SG11202005606VA
Inventor
Jorge Alsina-Fernandez
Tamer Coskun
Lili Guo
Hongchang Qu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202005606VA publication Critical patent/SG11202005606VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)
SG11202005606VA 2017-12-21 2018-12-14 Incretin analogs and uses thereof SG11202005606VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21
PCT/US2018/065663 WO2019125938A1 (en) 2017-12-21 2018-12-14 Incretin analogs and uses thereof

Publications (1)

Publication Number Publication Date
SG11202005606VA true SG11202005606VA (en) 2020-07-29

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005606VA SG11202005606VA (en) 2017-12-21 2018-12-14 Incretin analogs and uses thereof

Country Status (24)

Country Link
US (2) US11542313B2 (en)
EP (1) EP3727426A1 (en)
JP (2) JP6961838B2 (en)
KR (2) KR102622642B1 (en)
CN (1) CN111491658B (en)
AR (1) AR113486A1 (en)
AU (1) AU2018388962B2 (en)
BR (1) BR112020010244A2 (en)
CA (1) CA3084005C (en)
CL (1) CL2020001635A1 (en)
CO (1) CO2020006255A2 (en)
CR (1) CR20200255A (en)
DO (1) DOP2020000123A (en)
EA (1) EA202091290A1 (en)
EC (1) ECSP20032650A (en)
IL (1) IL275468A (en)
JO (1) JOP20200137A1 (en)
MA (1) MA51288A (en)
MX (1) MX2020006548A (en)
PE (1) PE20210162A1 (en)
PH (1) PH12020551025A1 (en)
SG (1) SG11202005606VA (en)
TW (2) TWI809515B (en)
WO (1) WO2019125938A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI809515B (en) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 Incretin analogs and uses thereof
AU2020334993B2 (en) * 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
TWI795698B (en) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 Incretin analogs and uses thereof
AU2021241257A1 (en) * 2020-03-25 2022-10-13 Takeda Pharmaceutical Company Limited QD dosing of GIP receptor agonist peptide compounds and uses thereof
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN114685642B (en) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 Pharmaceutically acceptable salt of incretin analogue, and preparation method and application thereof
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AR125086A1 (en) 2021-03-23 2023-06-07 Lilly Co Eli COMPOSITIONS CONTAINING INCRETIN ANALOGUES AND USES THEREOF
CA3219647A1 (en) 2021-05-26 2022-12-01 The United Bio-Technology (Hengqin) Co., Ltd. Multi agonists and use thereof
CN115572326A (en) * 2021-06-21 2023-01-06 广东东阳光药业有限公司 Triplex agonists of GLP-1, GCG and GIP receptors
EP4358994A1 (en) 2021-06-23 2024-05-01 Eli Lilly and Company An incretin analog for use in glycemic control and weight management
TWI828434B (en) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 Stapled peptide and application thereof
WO2023088140A1 (en) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 Stapled peptide and use thereof
CN116162147B (en) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 Long-acting insulin analogue
CN114957387B (en) * 2022-05-18 2023-06-20 华南理工大学 Almond polypeptide with blood sugar reducing effect and preparation method and application thereof
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024067662A1 (en) * 2022-09-28 2024-04-04 广东东阳光药业股份有限公司 Glp-1/gcg/gip triple-receptor agonist and use thereof
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
CN117024528B (en) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 Preparation method of Retatrutide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945500B (en) * 2008-06-17 2019-07-09 印第安纳大学研究及科技有限公司 Mixing agonist based on GIP is for treating metabolic disorder and obesity
BRPI1013588A2 (en) 2009-03-27 2016-04-19 Glaxo Group Ltd composition
CN102892425A (en) * 2010-01-20 2013-01-23 西兰制药公司 Treatment of cardiac conditions
AR080592A1 (en) * 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
WO2012153196A2 (en) * 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
AR092873A1 (en) 2012-09-26 2015-05-06 Cadila Healthcare Ltd PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS
TR201902516T4 (en) * 2013-11-06 2019-03-21 Zealand Pharma As Glucagon-glp-1-envy triple agonist compounds.
KR102310389B1 (en) * 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Gip-glp-1 dual agonist compounds and methods
JOP20200119A1 (en) * 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI783244B (en) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 Glucagon and glp-1 co-agonist compounds
TWI622596B (en) * 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
HRP20220995T1 (en) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Triple activator activating glucagon, glp-1 and gip receptor
EP3217027A1 (en) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Wide insert element for holding an anchoring bolt
TWI810937B (en) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 Incretin analogs and uses thereof
TWI809515B (en) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 Incretin analogs and uses thereof

Also Published As

Publication number Publication date
MA51288A (en) 2021-03-31
CO2020006255A2 (en) 2020-05-29
CL2020001635A1 (en) 2020-10-16
WO2019125938A1 (en) 2019-06-27
KR20200088419A (en) 2020-07-22
TWI744579B (en) 2021-11-01
IL275468A (en) 2020-08-31
KR20220133304A (en) 2022-10-04
AU2018388962B2 (en) 2020-11-19
TWI809515B (en) 2023-07-21
CA3084005C (en) 2024-01-02
CR20200255A (en) 2020-07-12
KR102444783B1 (en) 2022-09-19
EP3727426A1 (en) 2020-10-28
MX2020006548A (en) 2020-09-14
PE20210162A1 (en) 2021-01-26
PH12020551025A1 (en) 2021-09-06
BR112020010244A2 (en) 2020-10-13
US20200331980A1 (en) 2020-10-22
AR113486A1 (en) 2020-05-06
CN111491658A (en) 2020-08-04
CA3084005A1 (en) 2019-06-27
JP2022033724A (en) 2022-03-02
JP2021506955A (en) 2021-02-22
EA202091290A1 (en) 2020-09-10
US20230203121A1 (en) 2023-06-29
ECSP20032650A (en) 2020-07-31
AU2018388962A1 (en) 2020-06-04
TW202202518A (en) 2022-01-16
TW201938188A (en) 2019-10-01
CN111491658B (en) 2024-04-26
US11542313B2 (en) 2023-01-03
JP6961838B2 (en) 2021-11-05
JOP20200137A1 (en) 2022-10-30
KR102622642B1 (en) 2024-01-10
DOP2020000123A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
IL275468A (en) Incretin analogs and uses thereof
IL275469A (en) Incretin analogs and uses thereof
HK1243741A1 (en) Tnfrsf-binding agents and uses thereof
IL265922A (en) Tyk2 inhibitors and uses thereof
IL255577B (en) Tigit-binding agents and uses thereof
IL266109A (en) Tyk2 inhibitors and uses thereof
IL273236A (en) Pyrazolopyrimidinone compounds and uses thereof
PL3508580T3 (en) Novel promoter and use thereof
HK1256997A1 (en) Tyk2 inhibitors and uses thereof
HK1248690A1 (en) Tyk2 inhibitors and uses thereof
PL3250692T3 (en) Promoter and uses thereof
HK1251183A1 (en) Bioconjugates and uses thereof
EP3291676A4 (en) Mitragynine analogs and uses thereof
HK1248069A1 (en) Desacetoxytubulysin h and analogs thereof
IL248424B (en) Neuro-protective agents and uses thereof
IL254241A0 (en) Etv2 and uses thereof
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
HK1250915A1 (en) Composition and uses thereof
TWI561532B (en) Teicoplanin analogs and uses thereof
HK1246288A1 (en) S1pr2 antagonists and uses therefor
IL251588A0 (en) Methods and compositions for increasing the potency of antifungal agents
IL251289B (en) Novel peptide derivatives and uses thereof
GB201612150D0 (en) Modified peptide
SG11201610918RA (en) Peptides and uses thereof
IL248576A0 (en) Anti-louse composition and uses thereof